Welcome to our dedicated page for Xtl Biopharmaceu news (Ticker: XTLB), a resource for investors and traders seeking the latest updates and insights on Xtl Biopharmaceu stock.
XTL Biopharmaceuticals Ltd. reports developments as a foreign private issuer with American depositary shares and ordinary shares traded in Israel. The company is described as an IP portfolio company with hCDR1 intellectual property for lupus, including systemic lupus erythematosus, and Sjögren's syndrome that it has sublicensed.
Recurring news themes include ADS ratio and capital-structure actions, shareholder voting matters, governance updates, material agreements, and Nasdaq listing-status notices. Company updates also address the liquidation proceedings of its wholly owned subsidiary The Social Proxy Ltd. and other corporate-status matters affecting XTL's public-company profile.
XTL Biopharmaceuticals announced a definitive agreement to acquire The Social Proxy, an AI web data company. The deal involves issuing shares equating to 44.6% of XTL's issued share capital and paying $430,000. The acquisition aims to enhance XTL's asset portfolio with high-potential assets. The Social Proxy will operate as a subsidiary, with its shareholders appointing two board members. The transaction includes a $1.5 million private placement approved by shareholders, subject to closing conditions. XTL aims to leverage The Social Proxy's advanced IP-based platform for AI and BI applications.
Summary not available.
Summary not available.
Summary not available.